Ceapro Inc. Expands Collaborative Research Program with McMaster University to Develop an Inhalable Immuno-Therapeutic/-Prophylactic for COVID-19-Induced Lung Fibrosis
11 août 2022 09h05 HE
|
Ceapro Inc.
– Continuation of research with McMaster University to validate the anti-fibrotic properties of the Company’s PGX-Processed yeast beta glucan in experimental models of lung fibrosis and to pave the...
Ceapro Inc. Announces Publication of Positive Results for PGX-Processed Alginates Impregnated with CoQ10 in The Journal of Supercritical Fluids
09 août 2022 09h00 HE
|
Ceapro Inc.
– PGX Technology continues to demonstrate the ability to generate superior novel bioactive delivery systems – Findings from the collaborative project with the University of Alberta illustrate how...
Ceapro Bolsters Executive Management Team with Appointment of Sigrun Watson as Chief Revenue Officer
12 juil. 2022 08h35 HE
|
Ceapro Inc.
Recognized commercial leader with over 20 years of experience across diverse healthcare industries Appointment marks strategic step in driving Company towards next phase of growth EDMONTON, Alberta,...
Ceapro Announces Results of 2022 Shareholders’ Meeting
07 juin 2022 08h05 HE
|
Ceapro Inc.
EDMONTON, Alberta, June 07, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. to Present at the H.C. Wainwright Global Investment Conference
23 mai 2022 09h00 HE
|
Ceapro Inc.
EDMONTON, Alberta, May 23, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. Reports Record Financial Results for First Quarter 2022 and Provides Corporate Update
18 mai 2022 09h00 HE
|
Ceapro Inc.
– Best quarterly financial results in history of the Company – Q1 2022 sales of $6,172,000 vs $4,702,000 in Q1 2021, a 31% increase – Operating profit of $2,614,000 in Q1 2022 vs $515,000 in Q1...
Ceapro Inc. Present PGX Enabling Technology Case Study at the 13th International Symposium on Supercritical Fluids
13 mai 2022 09h00 HE
|
Ceapro Inc.
EDMONTON, Alberta, May 13, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. Announces Publication of Results for PGX-Processed Alginates in the Journal of CO2 Utilization
11 mai 2022 09h00 HE
|
Ceapro Inc.
– Findings from the collaborative project with the University of Alberta illustrate broad potential of the PGX Technology to generate the next generation of bioactive delivery systems – PGX...
Ceapro Inc. Announces Appointment of Geneviève Foster to Board of Directors
19 avr. 2022 08h05 HE
|
Ceapro Inc.
EDMONTON, Alberta, April 19, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and...
Ceapro Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
13 avr. 2022 09h00 HE
|
Ceapro Inc.
– FY 2021 record sales of $17,200,000 compared to $15,100,000 for FY 2020, representing a 14% increase year over year; Ceapro’s best sales performance in Company history – Net profit of $2,842,000...